Novel Treatments to prevent and treat hearing loss

In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.

Novel treatments to prevent and treat hearing loss

In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.

  Overview

Sound Pharmaceuticals (SPI) is a privately held biopharmaceutical company in Seattle, WA.

Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.

LEARN MORE

 Recent News

Sound Pharma initiates enrollment in pivotal Phase 3 clinical trial of SPI-1005 for the treatment of hearing loss and tinnitus in Meniere’s disease

By News Short

Sound Pharmaceuticals is pleased to announce that it has enrolled the first patient in its Phase 3 clinical trial involving SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3). Additionally, this marks the first Phase 3 trial of an investigational new drug for the treatment of Meniere’s Disease (MD).
Read More

Otoprotection

Oral treatments for acute and chronic hearing loss

LEARN MORE

Chemoprotection

Oral combination for the treatment of acute ototoxicity

LEARN MORE

Regeneration

Locally delivered treatments for hearing restoration

LEARN MORE